Skip to main content
Clinical Trials/NCT01174472
NCT01174472
Completed
Phase 2

Drug Eluting Versus Conventional Balloon Angioplasty for the Treatment of Failing Dialysis Access. A Prospective Randomized Single-Center Trial.

University of Patras1 site in 1 country40 target enrollmentMarch 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Dialysis
Sponsor
University of Patras
Enrollment
40
Locations
1
Primary Endpoint
Technical success
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The aim of the study is to compare the feasibility and the effectiveness, by means of immediate and long-term results, of drug eluting balloon (DEB) versus conventional balloon angioplasty for the treatment of failing dialysis access.

Detailed Description

In total 40 patients already diagnosed with hemodynamically significant stenosis of the dialysis AVF or AVG (including venous outflow lesions), programmed to undergo percutaneous transluminal angioplasty by our department, will sign informed consent and will be randomized to either receive DEB (Paclitaxel eluting balloon), or conventional balloon therapy. The protocol includes the description of patient's demographics (age, gender,dialysis access details, risk factors) and procedural details, as well as immediate results and long-term follow up.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
January 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

SIABLIS DIMITRIOS

Professor of Radiology

University of Patras

Eligibility Criteria

Inclusion Criteria

  • Angiographic and clinical diagnosis of dysfunctional dialysis access due to one or more stenotic lesions.
  • Patients with AVF or AVG
  • Fistula or graft or vessel diameter ranging from 3 mm up to 12 mm

Exclusion Criteria

  • Fistula or graft or vessel diameter \< 3 mm and \> 12 mm
  • History of severe allergic reaction to contrast media
  • Intolerance to aspirin and/or clopidogrel
  • Systemic coagulopathy or hypercoagulation disorders

Outcomes

Primary Outcomes

Technical success

Time Frame: 1 minute after the final balloon angioplasty

Residual stenosis of the treated lesion less than 30%, without any hemodynamicaly significant dissection (Type C)after the final angiography

Primary patency

Time Frame: 1 year

Angiographic visualization of a lesion with \<50% restenosis and no need for any additional repeat interventional procedure within the previously treated lesion, due to failing access.

Secondary Outcomes

  • Secondary patency(1 year)
  • Target lesion re-intervention (TLR)-free interval(1 year)
  • Major complications rates(Periprocedural and up to 1 year)
  • Minor complications rates(Periprocedural and up to 1 year follow-up)

Study Sites (1)

Loading locations...

Similar Trials